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A B S T R A C T
Purpose: Prescription errors are a common and potentially hazardous problem and may cause patient
harm. This review evaluates all new anti-epileptic drug (AED) outpatient prescriptions over one year and
reviews the subject literature.
Methods: A 12-month retrospective review of all outpatient prescriptions of AEDs within a large
Children’s Hospital. Copies of all prescriptions were obtained from the Trust’s Pharmacy. The evaluation
included the completeness of the required information, prescribing errors and the need for pharmacist
intervention before the drug could be dispensed. It did not address the severity of prescribing errors or
the potential harm to the patient.
Results: Two hundred and sixty two new prescriptions were evaluated. Incomplete prescriptions (that
omitted at least one piece of required information) were found in 72.1%. The most common omission was
the dose strength (mg/ml) or actual dose (mg) of the AED. No clinical diagnosis was documented in 62.6%
and in 22%, only the word ‘epilepsy’, was stated with no reference to the epilepsy syndrome or seizure
type. Pharmacist intervention was required in approximately 17% (approximately 1 in 6) of all
prescriptions before the AED could be dispensed.
Conclusion: This review highlights the importance of clinical information on prescriptions and that
incomplete or poor documentation may contribute to prescribing errors. It also emphasises the
importance of pharmacists in the identiﬁcation and correction or resolution of potential prescribing
errors. There is a need to develop a well-validated measure to assess the severity of prescribing errors
that will better address their clinical signiﬁcance and risk.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Prescription errors occur in all healthcare settings and all
healthcare professionals are encouraged to reduce prescribing errors
to optimise patient safety and reduce the consequences of such
errors. Studies from the USA suggest that at least one error per
prescription occurs in up to 1.9% of all prescriptions and is estimated
to cause harm in up to 1% of all inpatient episodes.1 Potential fatal
prescribing errors may occur in up to 1–2% of all prescriptions.2
The literature on paediatric prescribing has addressed medical
prescribing and pharmacological dispensing errors and interven-
tions by pharmacists or clinicians to reduce prescribing errors.2–11* Corresponding author. Tel.: +44 0151 252 5163; fax: +44 0151 252 5152.
E-mail address: Richard.appleton@alderhey.nhs.uk (R. Appleton).
http://dx.doi.org/10.1016/j.seizure.2014.06.010
1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights rePrescribing for children is more complicated than that for adults
because of their different ages, weights and metabolism of drugs.
This may be partly accounted for by prescriptions based on body
weight or body surface area. A recent study of outpatient paediatric
prescriptions suggested that 15% of children were dispensed
medications with a potential dosing error5; errors were more
frequent when the child’s weight was <35 kg with incorrect doses
identiﬁed in up to 32% of prescriptions.5 In contrast, another study
of inpatient prescriptions found that the most common error was
incomplete clinical or demographic information, with an overall
error rate of 19.1%.2
Anti-epileptic drugs (AEDs) add an extra level of complexity for
the prescriber. This is because there is a large number of AEDs that
offers the clinician a wide choice and even wider combination.
Many demonstrate signiﬁcant interactions with both other anti-
epileptic and non-anti-epileptic drugs; this may be of clinical
relevance because a signiﬁcant minority of children will requireserved.
Table 1
Numbers of anti-epileptic drugs (AEDs) prescribed (all
diagnoses).
AED Number (%)




















A.P. Murphy et al. / Seizure 23 (2014) 786–791 787two AEDs to achieve seizure control. Finally, all AEDs may be
associated with signiﬁcant adverse side effects. To demonstrate the
complexity of AED prescribing one study looked at AEDs and
changes between outpatient prescription and medication received
in ambulatory care at a later date. There were frequent and
signiﬁcant changes in medications and brands administered over
time.12
This paper evaluates all new prescriptions of AEDs issued
within the outpatient department of a large children’s hospital; to
the best of our knowledge it is the largest study that has reported
AED prescription in children. The paper focuses on the complete-
ness and accuracy of the prescriptions and need for pharmacist
intervention before the AED could be dispensed and within the
context of prescribing errors in children.
2. Methods
The study was a retrospective and observational study of all
new prescriptions for an AED issued from the general paediatric
and paediatric neurology outpatient departments over a 12 month
period (1st January 2012 to 31st December 2012). Repeat
prescriptions for an AED that children were already receiving
were excluded. All outpatient prescriptions in this institution (a
large children’s hospital) are completed in writing using a single
side and in-triplicate, A4 proforma.
All outpatient prescriptions are processed and medications
dispensed from the hospital’s single pharmacy department. It is
likely that all relevant prescriptions were identiﬁed for evaluation
during the study period primarily because all new outpatient
prescriptions are processed from this hospital’s only outpatient
pharmacy department.
Prescriptions were evaluated for the following information:
patient demographics, diagnosis/indication for the AED, medica-
tion details including clarity of instructions for dose regimes,
prescriber details and whether pharmacist intervention was
required to clarify or alter medication details and before the
medication could be dispensed. Data were collected on whether
the prescription was written by a consultant or a trainee but not
whether it was written by a member of the paediatric or paediatric
neurology team.
The epilepsy nurse specialists in our institution do not prescribe
AEDs.
All statistical analysis of data was performed using ‘Microsoft
Excel’.
Ethical approval was not required as this was a survey (audit).
However, the study was carried out in accordance with the
guidelines of the Declaration of Helsinki for medical research. All
data reported were anonymised.
3. Results
3.1. Prescription completion
Two hundred and sixty two new prescriptions were evaluated
for 243 patients; 19 patients received more than one new
prescription. Seventy three (27.9%) prescriptions were complete;
72.1% were incomplete with at least one piece of missing
information.
3.2. Diagnosis recorded
One hundred and sixty four (62.6%) of all prescriptions did not
state any diagnosis or indication for the prescribed medication. Of
the remaining 98, 50 cited only the single word, ‘Epilepsy’ and 48
cited a non-epileptic diagnosis – ‘Migraine’, ‘Behavioural problems’
and ‘Chronic pain’.3.3. Prescriber details
Prescribers recorded their details (designation and immediate
contact details) in only 109/262 (41.6%) of all prescriptions. Of the
prescriptions with prescriber details recorded, 71/109 (65.1%)
were written by a consultant (i.e. senior doctor), 19/109 (17.4%)
were by a registrar (i.e. paediatric specialist trainee) or senior
house ofﬁcer (i.e. junior doctor) and 19 (17.4%) were unclear as to
the grade of prescriber (un-recorded or illegible).
3.4. Choice of AED prescription (all diagnoses)
The most commonly prescribed AEDs were: sodium valproate
(48 [18.3%]), carbamazepine (36 [13.7%]) and levetiracetam (36
[13.7%]) (Table 1). For those prescriptions where there was a stated
non-epileptic diagnosis, gabapentin was the most commonly
prescribed AED.
3.5. Pharmacy intervention
Prescribers were contacted by a pharmacist in 44 prescriptions
(16.8%). Fifteen of the 44 prescriptions (34%) were due to an error
in dose or frequency of administration and the remaining 29 were
for other queries. Dosing errors were identiﬁed for the following
AEDs: carbamazepine, gabapentin, lamotrigine, levetiracetam,
midazolam and topiramate. All prescriptions with dosing errors
were amended prior to the AED being dispensed.
4. Discussion
Overall, 72.1% of the prescriptions were incorrectly or
inadequately completed. This compares unfavourably with similar
studies.2,5 Using the deﬁnition of a prescription error as described
by Dean et al.1 this review included the omission of required
information detail on the prescription proforma as an error
because this might still result in an ‘‘unintentional signiﬁcant
reduction in the probability of treatment being timely and
effective’’.1 Possible explanations for the high omission rate could
include time-constraint in clinic, illegible hand-writing or the
perception by the prescriber that the required information was
unnecessary. Electronic prescribing has been shown in some5,11
but not all9,10 studies to reduce prescribing errors. McPhillips et al.
determined whether their error rates were improved at a second
A.P. Murphy et al. / Seizure 23 (2014) 786–791788site with established electronic prescription and found no
signiﬁcant difference in errors.5
Although there were high numbers of incomplete or inadequate
prescriptions in the current study, no patients had their medication
incorrectly dispensed; this reﬂects the pharmacists’ review of each
prescription prior to the drug being dispensed.
The most commonly omitted information was the strength of
medication (mg/ml or tablet strength) in 48% of prescriptions. A
previous study found that the most common error was the dose
but no information was provided on omitted data.3
The clinical diagnosis on a prescription provides important
information and might increase the risk of an error if the indication
for a certain medication is not stated. ‘Epilepsy’ as a clinical
diagnosis is an inadequate indication for an AED. The choice of an
AED is determined by a number of factors, and most importantly by
the epilepsy syndrome or by seizure type (in those children with a
non-syndromic epilepsy).12 However, an epilepsy syndrome may
not be immediately identiﬁed at the time the patient’s epilepsy is
diagnosed and may take time to evolve. Clearly, treatment should
not be delayed pending the identiﬁcation of a speciﬁc epilepsy
syndrome and in this situation the choice of AED will be
determined by the seizure type(s). It would be difﬁcult to conﬁrm
the most appropriate choice of AED if this information has not been
recorded. Clearly, it is the clinician’s responsibility to prescribe the
most appropriate AED, but it might be reasonable to have the
choice of drug conﬁrmed by a clinical pharmacist.
Almost two thirds of the prescribers were consultants. The NICE
guidelines13 recommend that epilepsy should be diagnosed by
either a paediatric neurologist or a paediatrician with expertise in
epilepsy. It is unclear whether the junior doctor sought advice from
the consultant prior to writing the prescription but it would be
hoped that this would have occurred in most cases.
Pharmacist interventions evaluated within a Spanish paediatric
population found that most had a signiﬁcant impact on patient
health; up to 76% of all interventions were considered to have a
positive impact.3 Approximately 17% of prescribers in the current
study were contacted over prescription errors. No patients were
harmed as a result of medication error and this is likely to reﬂect
the impact of the pharmacist interventions in identifying a
potential error prior to the drug being dispensed.
Similar to an earlier study,3 we were unable to classify the
severity of the error and clinical importance of the intervention by
the clinical pharmacists because of the lack of a validated scoring
system. A robust scoring system would allow a comparison of
results in different units within a hospital and also between
hospitals.
4.1. Literature review
Prescription errors have focused primarily on inpatient-
prescribing and in three broad areas: the deﬁnition of and severity
of the error; prescribing errors by clinicians and potential
interventions including training and electronic prescribing; and
the use of clinical pharmacists to reduce error.
4.1.1. Deﬁnition of prescribing error
Prevalence rates of prescribing errors range widely from 2 to
79%, which reﬂects the absence of a robust, widely accepted and
pragmatic deﬁnition.14 A systematic review suggested that only 43
of the 203 reviewed studies used a similar deﬁnition developed by
the National Coordinating Council for Medication Error Reporting
and Prevention.15 The Council deﬁne a medication error as:
‘‘Any preventable event that may cause or lead to inappropriate
medication use or patient harm while the medication is in the
control of the health care professional, patient, or consumer.Such events may be related to professional practice, health care
products, procedures, and systems, including prescribing; order
communication; product labelling, packaging, and nomencla-
ture; compounding; dispensing; distribution; administration;
education; monitoring; and use.’’
Another deﬁnition developed using a two-stage Delphi
analysis1 suggested the following:
‘‘A clinically meaningful prescribing error occurs when, as a
result of a prescribing decision or prescription writing process,
there is an unintentional signiﬁcant (1) reduction in the
probability of treatment being timely and effective or (2)
increase in the risk of harm when compared with generally
accepted practice’’
Using the latter deﬁnition, an error rate was identiﬁed in 1.5% or
36,200 medication orders in the UK,16 similar to studies in the
USA.1,2 Of these, 54% were related to the dose and occurred more
commonly with prescriptions written during admission rather
than at discharge.16
Prescription errors that lead to potential harm are reported to
be less than 1%17 to as high as 19.7%18; it was approximately 17% of
all AED prescriptions in our institution.
4.1.2. Scales for assessing potential harm secondary to prescribing
error
Not all prescribing errors cause harm. A report of medication
errors in an adult tertiary neurology centre suggested that the
majority of errors (92.7%) caused no harm to patients.19 The rate of
prescribing error or omission of details within the current review
was high with 12% of all prescriptions requiring intervention by a
clinical pharmacist. However, we did not use a scale of potential
harm, either as a risk management/improvement tool or for
documentation purposes. The lack of a widely used tool for
identifying potential severity of harm secondary to a prescription
error reﬂects, in part, a lack of a consistently used deﬁnition of both
prescription error and what constitutes ‘harm’.1–5,8,11,13–15
A large systematic review of studies that used different tools to
assess the scale of the severity of prescribing errors found that, of
107 studies, slightly more than half (57%) used a scale of severity.
However, only two of the identiﬁed tools were reliable and
validated.20,21 In spite of a wide range of scales, none are widely
used in clinical practice. The authors emphasised the need to
develop a validated and accepted scale to assess the severity of a
prescribing error and to allow a comparison of errors between
institutions,22 a view shared by both Fernandez-Llamazares et al.3
and ourselves.
The identiﬁcation of prescribing errors is important for both
research and for clinical practice. A study of cytotoxic drug-
prescribing found that harm caused by a prescribing error was
usually due to multiple factors.23 Studies that have speciﬁcally
addressed AED-prescribing have emphasised that the transition of
patients from secondary to community or ambulatory care is a
potential time for errors in drug preparation (including brand) or
dose12,24; in epilepsy management, it is clearly important to
maintain consistent dosing regimens and brands of medication
when transferring care to optimise seizure control and avoid
toxicity.
4.1.3. Interventions to reduce prescribing error
4.1.3.1. Clinical pharmacist interventions. The importance of clini-
cal pharmacist intervention is well-recognised. Many medical
specialities with complex conditions that require polytherapy of
potentially toxic medications routinely include clinical pharma-
cists on ward rounds or in outpatient clinics.25 Studies have
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outcome measures including symptom-control, monitoring of
blood indices and patient satisfaction. Statistically signiﬁcant
improvements in some aspects of patient management have been
seen with more pharmacist intervention or integration within the
clinical team.26 A Cochrane Review of the role of pharmacists in the
outpatient department found a reported improvement of patient
outcomes in 10 of 13 studies.27,28 Predictably, studies have
demonstrated that the employment of clinical pharmacists can
prevent error, particularly with their input on ward rounds and
inpatient prescriptions.26,29,30 As yet, no study has speciﬁcally
assessed improvements in quality of life.27 It has been suggested
that trainee pharmacists are better at identifying errors than other
nurses or doctors. It has been suggested that this may reﬂect a
different emphasis in their training compared with other
professional.31 It is standard practice in our institution for a
designated clinical pharmacist to be allocated to all wards; this
reduces potential prescribing errors and expedites the discharge of
all patients with take-home drugs.
Approximately 17% of prescribers in the current review were
contacted about prescription errors most of which could poten-
tially have led to patient harm, through under- or over-dosing or
incorrect choice of AED. The fact that no patient did come to harm
reﬂects the impact of the clinical pharmacist in the identiﬁcation of
the error prior to the drug being dispensed.
One study that compared prescribing errors in two groups of
patients demonstrated that these were halved in the group with
intervention by a clinical pharmacist.26 This was supported by the
ﬁndings of a Spanish population where of all interventions, 76%
were considered to have had a positive impact.3 The authors also
used a scale of potential harm and this suggested that 49 of the
1475 pharmacist interventions were to correct a ‘‘dosage error that
could have resulted in potentially toxic concentrations’’. Another
study undertook a cost-beneﬁt analysis of pharmacists and their
role in preventing prescribing error32; calculations were based
upon a prescribing error rate of 1.5% and it was suggested that
pharmacists could provide a signiﬁcant economic beneﬁt.32
A likely criticism of pharmacists’ interventions may be that
their advice on speciﬁc drug or dose recommendations will be
relatively rigid and based on published guidelines including the
British National Formulary (BNF) and British National Formulary
for Children (BNF-C) or the National Institute for Health and
Clinical Excellence (NICE). This does not necessarily take account
of the knowledge, specialism and clinical experience of the
prescriber who may have been prescribing a drug outside the
recommended doses or regime for some years without harm to the
patient. However, we feel that the pharmacist has an important
role in at least questioning any potentially harmful error and this
includes the choice of AED, its starting or maintenance dose or
dosing regimen. None of the pharmacy interventions in the
current study were considered to be inappropriate and none were
detrimental to patient care. The fact that only 56% of prescriptions
included a legible or clear diagnosis also allowed the pharmacist
to question the indication for and choice of the prescribed anti-
epileptic drug.
4.1.3.2. Training and e-learning prescribing packages. It could be
expected that human error is likely to be the largest source of
prescribing errors. Prescribers may not be in an ‘ideal situation’ to
fully concentrate on the task of prescribing and may be inﬂuenced
by fatigue, level of experience, formalised training and concentra-
tion, particularly if the ward environment is very busy. One study
that examined a large number (45,366) of ‘orders’ (prescriptions,
laboratory tests) found no statistical correlation between the time
the order was written with a doctor’s single 24-h shift and either
the number, or signiﬁcance of, prescribing errors. The study did nottake into account potential cumulative effects of medical rotas or
the medical speciality.33
A wrong dose calculation is obviously likely to lead to
prescribing errors. When testing paediatric trainees under ‘ideal’
(i.e. examination) conditions, no correlation was found between
seniority and error, although more potentially severe medication
errors (speciﬁcally, a tenfold dose error) were perpetrated by ﬁrst
or second year junior doctors (residents).34 The same study
suggested that different healthcare professionals receive a differ-
ent focus regarding prescriptions of medication; nursing staff
receive more detailed training on correct drug dose calculation
than equivalent medical staff.33
Several studies have tried to evaluate, and have shown, a
reduction of prescription errors following taught, self-directed or
e-learning interventions. Findings are difﬁcult to compare because
studies report on different training packages, training formats and
intended cohort of learners (medical/nursing and undergraduate/
postgraduate).35 Major criticisms of these studies are that the
sample sizes are small and outcome measures are based on
examination-style assessments which do not typically reﬂect
routine clinical practice.
A systematic review of educational interventions found that
only one tool has sufﬁcient evidence to support its effectiveness,
with six studies identiﬁed as supporting.35 This is teaching sessions
based on the ‘WHO good prescribing guide’ which has shown a
statistically signiﬁcant improvement in prescribing post interven-
tion.36–41 However, the use of teaching programmes to reduce
prescribing errors remains unproven, primarily because of a lack of
a reliable and validated learning tool. It is worth noting that almost
all studies that have evaluated teaching programmes focus on
medical students or junior doctors. In the current review, high
levels of error or omission of details still occurred despite most
prescriptions being completed by a consultant (67.7%).
Although it could be argued that the added complexity of
paediatric AED-prescribing increases the risk of prescribing errors,
this would seem untenable for experienced consultants and would
not explain the omission of important information on patient
weight, formulation and dose regimen of the AED and indication
for the drug’s use.
4.1.4. Electronic prescribing (e-prescribing)
Electronic prescribing is regarded by many as the obvious
method to reduce errors and speciﬁcally those that relate to
legibility. These include the initiative, ‘Safer Hospitals Safer Wards’
proposed by the Department of Health and NHS England. Funds are
to be made available to help adopt safe electronic record-keeping
and prescriptions with integrated electronic versions.42 Of 101
hospitals recently surveyed, 69% used e-prescribing.42 Studies that
support e-prescribing43–46,48–50 have focused on inpatient pre-
scriptions41 and emphasised the main beneﬁt of legibility.48–50
In our institution, all outpatient prescriptions are hand-written
using an A4-size proforma. Our review identiﬁed that ﬁve (1.9%) of
all prescriptions included illegible doses or dose regimens and
could not dispensed. An additional 10.1% also included illegible
information but this did not necessitate intervention by a
pharmacist. Additional reported beneﬁts of e-prescribing include:
automated prompts on any aspects of prescribing (such as
interactions), limits on prescribable dosages (e.g. to reduce tenfold
dose errors), and simpliﬁed medication-selection through ‘drop-
down’ menus and recommended doses and timings of doses.
However, e-prescribing is not infallible and potential dis-
advantages include cost, compatibility of existing systems,
computer or network failures and appropriate training. Some
studies have suggested an increase in total errors47 but a decrease
in their clinical signiﬁcance.48 A systemic review of e-prescribing
emphasised that while nine of the 13 studies reviewed showed a
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severity of error and those that did showed decreases mostly in
minor errors.51 This may relate to drop-down lists which although
designed to be quick, may, in an inattentive prescriber, result in an
incorrect selection (e.g. patient, drug, dose regimen or preparation)
or duplicate drug prescription.48,49 The most commonly identiﬁed
discrepancy was one over administration instructions in a study
that compared electronic prescriptions with the medications
subsequently dispensed.52
A study of a ‘closed-loop prescribing and administering system’
that used barcodes of inpatient prescriptions resulted in a reduced
number of medication administration errors but an increase (p
value <0.05) in both prescribing and dispensing times.53 The
systematic review concluded that the existing evidence behind
electronic prescribing reducing error rates was ‘not compelling’
and that currently, support for e-prescribing is based on small scale
studies.52
Despite these potential difﬁculties, It is likely that e-prescribing
will become the standard method of prescribing although there
will always be a need for a paper back-up in the event of IT failure.
4.1.5. Other interventions to optimise prescribing accuracy
Limited evidence suggests that other approaches may also
improve inpatient prescribing practice, including standardisation
of prescription sources,52 prescription proformas,54 pocket tables
with dosing guidelines, pocket PC-based automatic dosage
calculation,55 dedicated prescribing stations and daily feedback.56
Studies that have evaluated the beneﬁts of reducing prescriber-
distraction or speciﬁc drug dose calculation devices have shown up
to a 10% reduction in prescribing errors.53 Some of these
interventions may also be applicable for outpatient-prescribing.
5. Conclusion
The current study has demonstrated a high rate of prescribing
errors of anti-epileptic dugs within a single institution (a large
children’s hospital). At least one omission was identiﬁed in over
70% of all prescriptions and one in six prescriptions required
intervention by a clinical pharmacist before the drug could be
dispensed. This clearly indicates a clear need to reduce prescrip-
tions errors, a conclusion supported by the ﬁndings of other, larger
studies. Prescription errors may result in signiﬁcant patient harm
with potential clinical and legal consequences with wider
implications for the National Health Service.
The development of a robust and validated scale to score the
severity of prescription errors and their clinical importance is also
important for both clinical and research purposes.
The reduction of prescribing errors could be achieved using
different approaches, including improved training of prescribers,
the use of electronic prescribing and closer involvement within
clinical teams by a clinical pharmacist.
The results of this survey have been presented to the paediatric
neurology, general paediatric and pharmacy departments within
the hospital; the survey will be repeated within the near future.
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